In a review of repurposing medications for pulmonary arterial hypertension treatment, dichloroacetate, metformin, and rosiglitazone/pioglitazone had the most preclinical data to support their use.
Balloon pulmonary angioplasty was considered safe and effective even in patients considered “oldest-old” with chronic thromboembolic pulmonary hypertension.
Investigators sought to differentiate cardiac exercise responses in patients with pulmonary arterial hypertension stratified according to established measurements of disease severity.
Patients with systemic sclerosis-associated pulmonary arterial hypertension who were given combination sequential therapy had improved survival rates compared with patients receiving upfront combination or monotherapy.
Investigators assessed the prevalence of perioperative adverse cardiovascular events after noncardiac surgery in patients with and without pulmonary hypertension.
The REVEAL 2.0 three category score was better at discriminating risks in patients with pulmonary arterial hypertension than similar tools such as COMPERA and FPHR.
In patients with pulmonary arterial hypertension, high baseline right atrial pressure, left heart disease, and pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis are valuable predictors of pulmonary edema.
